PHASE I TRIAL OF A BIVALENT GANGLIOSIDES VACCINE IN COMBINATION WITH β-GLUCAN: FOR HIGH-RISK NEUROBLASTOMA IN SECOND OR LATER REMISSION

BACKGROUND: To report on a phase I trial designed to find the maximally tolerated dose in children of the immunological adjuvant OPT-821 in a vaccine containing neuroblastoma-associated antigens (GD2 and GD3) (Clinicaltrials.gov NCT00911560). Secondary objectives were to obtain preliminary data on i...

Full description

Saved in:
Bibliographic Details
Published in:Clin Cancer Res
Main Authors: Kushner, Brian H., Cheung, Irene Y., Modak, Shakeel, Kramer, Kim, Ragupathi, Govind, Cheung, Nai-Kong V.
Format: Artigo
Language:Inglês
Published: 2014
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5592799/
https://ncbi.nlm.nih.gov/pubmed/24520094
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-1012
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items